We had sequenced a cDNA of calcium oxalate urinary stone protein extracted with 0.1 M EDTA. cDNA sequences showed complete homology between urinary stone protein and human osteopontin (OPN, bone sialoprotein I). In the present study, we investigated the expression of OPN mRNA in the rat kidney in an experimental model of renal stone formation using glyoxylic acid and 1,25-dihydroxyvitamin D3 (D3). In the renal stone formation model with and without renal failure, OPN mRNA was shown to be localized by in situ hybridization using an OPN cRNA probe mainly in the distal convoluted tubule of the kidney, and was enhanced compared with the normal control which was sporadically positive. By Northern blot analysis, the expression of OPN mRNA was shown to be increased by about 5.2-fold in the renal stone formation model and 2.3-fold in D3-administered rats compared with controls. However, no change in the expression of OPN mRNA was observed in an acute renal failure model induced by gentamicin or in rats administered glycoxylic acid alone. Therefore, the promotion of OPN mRNA expression was intrinsic to this stone formation model, and not secondary to acute renal failure because of obstruction by microcrystals in the renal tubules or gentamicin.

Keywords:
Osteopontin, Kidney stone, Glyoxylic acid, 1,25-Dihydroxyvitamin D3, Gentamicin
This content is only available via PDF.
© 1995 S. Karger AG, Basel
1995
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.